

RSV Immunizations for Infants

Nirsevimab (brand name Beyfortus™) and clesrovimab (brand name Enflonsia™)

Nirsevimab and clesrovimab are monoclonal antibodies that help prevent serious illness from RSV. They are not vaccines, but immunizations, and they provide passive immunity. Nirsevimab and clesrovimab are given through intramuscular injection and provide protection for ~6 months.

Recommendations

Both nirsevimab and clesrovimab are recommended for:

- Newborns who are born during the RSV season.
- Infants under 8 months old who are entering their first RSV season.

Nirsevimab is also recommended for:

- Children 8 months up to 19 months who are at risk of severe RSV disease*.

The formulation of these products does not change from year to year. Nirsevimab and clesrovimab are not recommended for most infants born to a person who received Abrysvo**.

Dosage and Packaging

Nirsevimab

Pre-filled syringes:

- 50 mg/0.5 mL with purple plunger rod (for infants weighing <5 kg)

or

- 100 mg/mL with light blue plunger rod (for infants weighing ≥5kg)

*Children up to 19 months, regardless of body weight, receiving nirsevimab in their second RSV season should receive one 200 mg dose administered as two IM injections (two x 100 mg).

~36-month shelf life.

Clesrovimab

Pre-filled syringes of 105mg/0.7 ml with pink plunger rod

All infants receive the same dose, regardless of weight.

~30-month shelf life.

Date of Birth:

April 1 through
September 30



Start
immunizing
October 1



Date of Birth:

October 1
through March 31



Immunize within one
week after birth,
ideally before
hospital discharge

Can RSV immunizations be administered the same day as other immunizations?

Yes. Nirsevimab and clesrovimab may be given concomitantly with childhood vaccines, but should be administered in separate syringes, at different injection sites.

What are the common side effects?

Common side effects may include rash and irritation at the injection site.

Can an infant who tested positive for RSV receive an RSV immunization?

RSV infection does not impact an infant's eligibility for nirsevimab or clesrovimab and there is no minimum interval recommended between infection and immunization.

****If Abrysvo was given during pregnancy, should an infant receive nirsevimab or clesrovimab?**

Nirsevimab and clesrovimab are not recommended for most infants born to a person who received Abrysvo. The exception is for infants where less than 14 days have elapsed between Abrysvo vaccination and birth, or where the parent's vaccine status is unknown.

Abrysvo is given between 32-36 weeks' gestation during September through January to protect infants for up to 6 months after birth. Abrysvo is available via medical and pharmacy billing without a prior authorization or submission of additional documentation of weeks of gestation for individuals 19 years of age and older. More information from [HFS](#).

Note: Palivizumab is no longer routinely recommended for use.

Reimbursement and Coding

Proprietary Name	Manufacturer	Unit of Sale NDC11	CVX Description	CVX Code	MX Code	CPT Code
BEYFORTUS	Sanofi Pasteur Inc.	49281-0575-15	RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months	306	PMC	90380
BEYFORTUS	Sanofi Pasteur Inc.	49281-0574-15	RSV, mAb, nirsevimab-alip, 1mL, neonate to 24 months	307	PMC	90381
ENFLONISIA	Merck & Co., Inc.	0006-5073-01 (carton of 1) 0006-5073-02 (carton of 10)	RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, preservative free	332	MSD	90382

Administrative codes 96380 and 96381 can be used to reflect administration with counseling (96380) and administration without counseling (96381).